KLRK1 and hematologic disorder: In addition, NKG2D ligands are also expressed on immunosuppressive cells, such as regulatory T cells and myeloid-derived suppressor cells, making NKG2D-CAR T cell therapy an attractive option in hematological malignancies and solid tumors (55).